Communist China is reportedly providing military assistance to the embattled Iranian regime, according to a leading U.S. military think tank and other reporting. The Institute for the Study of War ...

Arizona set a program record with its 36th win and rallied from its largest halftime deficit in an NCAA Tournament game in a 79-64 win over Purdue on Saturday in the West Regional Final. The Wildcats ...

Get the latest federal technology news delivered to your inbox. The General Services Administration has released a draft of several changes it plans for the Multiple Award Schedule program, a ...

The General Services Administration has released a draft of several changes it plans for the Multiple Award Schedule program, a government-wide initiative for agencies to acquire commercial products ...

Penn State cruised to its fourth straight title at the Big Ten Wrestling Championships, winning a program-record seven individual titles in the process. Penn State also set a school-record with 184 ...

Poplar Therapeutics, Inc., a clinical-stage immunology company developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions, today announced the closing of its Series A ...

A sign for the U.S. Department of State is seen on the outside of the Harry S. Truman Federal Building on Oct. 8, 2024 in Washington, DC. (Photo by Kevin Dietsch/Getty Images) The Department of State ...

NORWALK — Overcrowding around apartment developments, double parking and blocked sight lines were just a few of the many parking issues Norwalk residents brought up to city officials to consider for ...

Phase III is intended to generate meaningful biological data on potential drug compounds prioritized by YuvaBio’s classifier, which applies proprietary machine-learning methods to identify candidates ...

The state cited Care Crossings for more than 100 breaches of state law or rules. Whistleblowers say the business has long had issues. A new state report has cited a Stillwater-area substance abuse ...

Takeda has given up on an AstraZeneca-partnered neurological disorder program after the therapy flunked a phase 2 study. The Japanese pharma had been evaluating the alpha-synuclein antibody, called ...